Eliminating accumulated losses through capital reductions and transfers of surplus
First written in FY2020-Q2. 2 of 4 entries say "Achieved", first in FY2020. Latest entry: FY2023-Q1.
125 other companies' latest entry also says "Achieved".
- FY2023-Q1AchievedAnnual report
「At a meeting of the Board of Directors held on 22 September 2022, the Company resolved to submit to the 17th Annual General Meeting of Shareholders, held on 26 October 2022, proposals for reducing the amounts of capital and the capital reserve and disposing of surplus as set out below. The proposals were approved at the annual general meeting and took effect on 1 December 2022.」
The procedure for reducing capital and the capital reserve and transferring other capital surplus to retained earnings brought forward for use in eliminating the deficit was approved and took effect on 1 December 2022. - FY2020AchievedAnnual report
「During the current fiscal year, the Company recorded operating income and net income as a result of eliminating the deficit and generating revenue under a new agreement aimed at expanding the indications for Redasemtide. The negative balance of retained earnings brought forward has consequently been eliminated.」
Following the elimination of the deficit through a reduction in capital and transfers of surplus, the negative balance of retained earnings brought forward was confirmed to have been eliminated. - FY2020-Q3RestatedAnnual report
「The reduction in capital took effect on 1 December 2019, reducing capital by ¥4,675.501 million, increasing the capital reserve by ¥3,656.365 million and increasing other capital surplus by ¥1,019.135 million. The accumulated losses were eliminated by transferring the increased other capital surplus of ¥1,019.135 million to retained earnings brought forward.」
The capital policy concerning a reduction in capital, transfers to capital surplus and the elimination of accumulated losses has been reaffirmed. - FY2020-Q2First statedAnnual report
「The reduction in capital took effect on 1 December 2019, reducing capital by ¥4,675.501 million, increasing the capital reserve by ¥3,656.365 million and increasing other capital surplus by ¥1,019.135 million. The accumulated losses were eliminated by transferring the increased other capital surplus of ¥1,019.135 million to retained earnings brought forward.」
The Company's capital policy was described for the first time: reducing capital, transferring the amount to the capital reserve and other capital surplus, then transferring other capital surplus to retained earnings brought forward to eliminate accumulated losses.